Does the media prefer HIK or INDV?

In the previous week, Hikma Pharmaceuticals had 3 more articles in the media than Indivior. MarketBeat recorded 5 mentions for Hikma Pharmaceuticals and 2 mentions for Indivior. Hikma Pharmaceuticals' average media sentiment score of 0.17 beat Indivior's score of 0.17 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hikma Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer HIK or AMYT?

Hikma Pharmaceuticals presently has a consensus target price of GBX 1,687, indicating a potential downside of 0.71%. Given Amryt Pharma's higher possible upside, analysts plainly believe Amryt Pharma is more favorable than Hikma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hikma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Amryt Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Hikma Pharmaceuticals (HIK) Competitors

GBX 1,699 +128.00 (+8.15%)

As of 12:28 PM Eastern

Compare

HIK vs. INDV, HCM, AMYT, APH, and AGY

Should you buy Hikma Pharmaceuticals stock or one of its competitors? MarketBeat compares Hikma Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hikma Pharmaceuticals include Indivior (INDV), HUTCHMED (HCM), Amryt Pharma (AMYT), Alliance Pharma (APH), and Allergy Therapeutics (AGY).

How does Hikma Pharmaceuticals compare to Indivior?

Hikma Pharmaceuticals (LON:HIK) and Indivior (LON:INDV) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Hikma Pharmaceuticals has a net margin of 12.00% compared to Indivior's net margin of 11.44%. Hikma Pharmaceuticals' return on equity of 15.83% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	12.00%	15.83%	9.40%
Indivior	11.44%	-23.90%	2.37%

In the previous week, Hikma Pharmaceuticals had 3 more articles in the media than Indivior. MarketBeat recorded 5 mentions for Hikma Pharmaceuticals and 2 mentions for Indivior. Hikma Pharmaceuticals' average media sentiment score of 0.17 beat Indivior's score of 0.17 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hikma Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hikma Pharmaceuticals has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.35B	1.07	£353.21M	£181.00	9.39
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.0% of Indivior shares are owned by institutional investors. 21.9% of Hikma Pharmaceuticals shares are owned by company insiders. Comparatively, 3.4% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Hikma Pharmaceuticals has a beta of 0.654, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Indivior has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Hikma Pharmaceuticals presently has a consensus target price of GBX 1,687, suggesting a potential downside of 0.71%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Hikma Pharmaceuticals pays an annual dividend of GBX 84.14 per share and has a dividend yield of 5.0%. Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. Hikma Pharmaceuticals pays out 46.5% of its earnings in the form of a dividend. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Hikma Pharmaceuticals beats Indivior on 15 of the 18 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to HUTCHMED?

Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.35B	1.07	£353.21M	£181.00	9.39
HUTCHMED	£549.12M	2.73	-£52.98M	£53.00	3.29

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.4% of HUTCHMED shares are owned by institutional investors. 21.9% of Hikma Pharmaceuticals shares are owned by company insiders. Comparatively, 2.8% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

HUTCHMED has a net margin of 163.84% compared to Hikma Pharmaceuticals' net margin of 12.00%. HUTCHMED's return on equity of 36.88% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	12.00%	15.83%	9.40%
HUTCHMED	163.84%	36.88%	-5.90%

In the previous week, Hikma Pharmaceuticals had 5 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Hikma Pharmaceuticals and 0 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 0.17 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Neutral
HUTCHMED	Neutral

Hikma Pharmaceuticals currently has a consensus target price of GBX 1,687, suggesting a potential downside of 0.71%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Hikma Pharmaceuticals has a beta of 0.654, indicating that its share price is 35% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.428, indicating that its share price is 57% less volatile than the broader market.

Summary

Hikma Pharmaceuticals beats HUTCHMED on 13 of the 16 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Amryt Pharma?

Hikma Pharmaceuticals (LON:HIK) and Amryt Pharma (LON:AMYT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

In the previous week, Hikma Pharmaceuticals had 5 more articles in the media than Amryt Pharma. MarketBeat recorded 5 mentions for Hikma Pharmaceuticals and 0 mentions for Amryt Pharma. Hikma Pharmaceuticals' average media sentiment score of 0.17 beat Amryt Pharma's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Neutral
Amryt Pharma	Neutral

Hikma Pharmaceuticals has a net margin of 12.00% compared to Amryt Pharma's net margin of 0.00%. Hikma Pharmaceuticals' return on equity of 15.83% beat Amryt Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	12.00%	15.83%	9.40%
Amryt Pharma	N/A	N/A	N/A

Hikma Pharmaceuticals presently has a consensus target price of GBX 1,687, indicating a potential downside of 0.71%. Given Amryt Pharma's higher possible upside, analysts plainly believe Amryt Pharma is more favorable than Hikma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amryt Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. 21.9% of Hikma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Hikma Pharmaceuticals has higher revenue and earnings than Amryt Pharma. Amryt Pharma is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.35B	1.07	£353.21M	£181.00	9.39
Amryt Pharma	£210.24M	0.00	N/A	-£33.00	N/A

Summary

Hikma Pharmaceuticals beats Amryt Pharma on 12 of the 13 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Alliance Pharma?

Hikma Pharmaceuticals (LON:HIK) and Alliance Pharma (LON:APH) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Hikma Pharmaceuticals presently has a consensus target price of GBX 1,687, suggesting a potential downside of 0.71%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Hikma Pharmaceuticals is more favorable than Alliance Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alliance Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Hikma Pharmaceuticals had 5 more articles in the media than Alliance Pharma. MarketBeat recorded 5 mentions for Hikma Pharmaceuticals and 0 mentions for Alliance Pharma. Hikma Pharmaceuticals' average media sentiment score of 0.17 beat Alliance Pharma's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Neutral
Alliance Pharma	Neutral

Hikma Pharmaceuticals has a net margin of 12.00% compared to Alliance Pharma's net margin of -6.00%. Hikma Pharmaceuticals' return on equity of 15.83% beat Alliance Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	12.00%	15.83%	9.40%
Alliance Pharma	-6.00%	-5.04%	5.98%

Hikma Pharmaceuticals has a beta of 0.654, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Alliance Pharma has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Hikma Pharmaceuticals has higher revenue and earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.35B	1.07	£353.21M	£181.00	9.39
Alliance Pharma	£183.50M	1.91	-£33.65M	-£6.20	N/A

Hikma Pharmaceuticals pays an annual dividend of GBX 84.14 per share and has a dividend yield of 5.0%. Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 3.1%. Hikma Pharmaceuticals pays out 46.5% of its earnings in the form of a dividend. Alliance Pharma pays out -32.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.3% of Alliance Pharma shares are owned by institutional investors. 21.9% of Hikma Pharmaceuticals shares are owned by insiders. Comparatively, 12.0% of Alliance Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Hikma Pharmaceuticals beats Alliance Pharma on 14 of the 18 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Allergy Therapeutics?

Hikma Pharmaceuticals (LON:HIK) and Allergy Therapeutics (LON:AGY) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Hikma Pharmaceuticals has a net margin of 12.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	12.00%	15.83%	9.40%
Allergy Therapeutics	-85.46%	409.00%	-34.76%

Hikma Pharmaceuticals has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.35B	1.07	£353.21M	£181.00	9.39
Allergy Therapeutics	£57.29M	5.87	-£52.59M	-£0.97	N/A

Hikma Pharmaceuticals has a beta of 0.654, indicating that its share price is 35% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.872, indicating that its share price is 13% less volatile than the broader market.

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are held by institutional investors. 21.9% of Hikma Pharmaceuticals shares are held by insiders. Comparatively, 3.6% of Allergy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Hikma Pharmaceuticals presently has a consensus target price of GBX 1,687, suggesting a potential downside of 0.71%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Hikma Pharmaceuticals is more favorable than Allergy Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Allergy Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Hikma Pharmaceuticals had 5 more articles in the media than Allergy Therapeutics. MarketBeat recorded 5 mentions for Hikma Pharmaceuticals and 0 mentions for Allergy Therapeutics. Hikma Pharmaceuticals' average media sentiment score of 0.17 beat Allergy Therapeutics' score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Neutral
Allergy Therapeutics	Neutral

Summary

Hikma Pharmaceuticals beats Allergy Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Hikma Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HIK vs. The Competition

Export

Metric	Hikma Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£3.58B	£11.79B	£6.93B	£2.87B
Dividend Yield	3.89%	2.73%	2.60%	6.13%
P/E Ratio	9.39	794.00	281.16	369.49
Price / Sales	1.07	750.89	591.75	83,955.55
Price / Cash	8.34	72.42	71.79	27.89
Price / Book	1.65	10.72	12.86	7.07
Net Income	£353.21M	£2.82B	£3.49B	£5.89B
7 Day Performance	6.59%	2.82%	2.64%	1.18%
1 Month Performance	9.34%	-1.31%	-2.64%	0.90%
1 Year Performance	-9.82%	195.96%	76.00%	75.31%

Hikma Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HIK Hikma Pharmaceuticals	2.0842 of 5 stars	GBX 1,699 +8.1%	GBX 1,687 -0.7%	-18.0%	£3.58B	£3.35B	9.39	9,100	News Coverage
INDV Indivior	N/A	GBX 1,238 +1.6%	N/A	+0.0%	£1.93B	£1.40B	N/A	1,000	Gap Up High Trading Volume
HCM HUTCHMED	N/A	GBX 174 -1.4%	N/A	-34.8%	£1.50B	£548.51M	3.28	1,760	Gap Down
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	£457.11M	£210.24M	N/A	290	Gap Down
APH Alliance Pharma	N/A	GBX 64.70 flat	N/A	N/A	£350.32M	£183.50M	N/A	91,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HIK) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hikma Pharmaceuticals (HIK) Competitors

HIK vs. INDV, HCM, AMYT, APH, and AGY

How does Hikma Pharmaceuticals compare to Indivior?

Summary

How does Hikma Pharmaceuticals compare to HUTCHMED?

Summary

How does Hikma Pharmaceuticals compare to Amryt Pharma?

Summary

How does Hikma Pharmaceuticals compare to Alliance Pharma?

Summary

How does Hikma Pharmaceuticals compare to Allergy Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIK vs. The Competition

Hikma Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hikma Pharmaceuticals (HIK) Competitors

HIK vs. INDV, HCM, AMYT, APH, and AGY

How does Hikma Pharmaceuticals compare to Indivior?

Is HIK or INDV more profitable?

Does the media prefer HIK or INDV?

Which has preferable valuation and earnings, HIK or INDV?

Do insiders and institutionals hold more shares of HIK or INDV?

Which has more volatility & risk, HIK or INDV?

Do analysts recommend HIK or INDV?

Is HIK or INDV a better dividend stock?

Summary

How does Hikma Pharmaceuticals compare to HUTCHMED?

Which has higher earnings & valuation, HIK or HCM?

Do insiders & institutionals hold more shares of HIK or HCM?

Is HIK or HCM more profitable?

Does the media prefer HIK or HCM?

Do analysts recommend HIK or HCM?

Which has more risk and volatility, HIK or HCM?

Summary

How does Hikma Pharmaceuticals compare to Amryt Pharma?

Does the media favor HIK or AMYT?

Is HIK or AMYT more profitable?

Do analysts prefer HIK or AMYT?

Do institutionals and insiders believe in HIK or AMYT?

Which has higher earnings & valuation, HIK or AMYT?

Summary

How does Hikma Pharmaceuticals compare to Alliance Pharma?

Do analysts recommend HIK or APH?

Does the media refer more to HIK or APH?

Is HIK or APH more profitable?

Which has more risk & volatility, HIK or APH?

Which has better valuation & earnings, HIK or APH?

Is HIK or APH a better dividend stock?

Do institutionals & insiders hold more shares of HIK or APH?

Summary

How does Hikma Pharmaceuticals compare to Allergy Therapeutics?

Is HIK or AGY more profitable?

Which has stronger valuation and earnings, HIK or AGY?

Which has more risk and volatility, HIK or AGY?

Do insiders and institutionals believe in HIK or AGY?

Do analysts rate HIK or AGY?

Does the media refer more to HIK or AGY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIK vs. The Competition

Hikma Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools